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1 
SCOPE AND PLAN OF WORK 
 Colorectal carcinoma is the second leading cancer killer and third 
most common cancer through   out the world .The incidence of colorectal 
cancer is second for men next to lung cancer and second in women next 
to breast cancer. Surgery, radiation therapy and chemotherapy are the 
three type of treatment commonly used. The main problem in Colorectal 
cancer is that 30-50% of patients have advanced disease when they are 
diagnosed and occurs most frequently after the age of 50, approximately 
7% are seen in patients less than 40 years of age.  
Capecitabine is a new drug for orally administered drug is widely 
used for the treatment of colorectal cancer. It is readily absorbed from 
gastrointestinal tract. It is a fluoro pyrimidine which is converted into  
5-fluoro uracil (5-FU) after entering the tumour cells. It is unstable in acidic 
condition of the stomach. Less than 50% is bonded to plasma protein, It 
has a peak plasma concentration of 1.5 hours. It is metabolized in the liver 
by 60 K Da Carboxylestesterase. By converting into controlled, site 
specific release dosage form first pass metabolism can be minimized, 
bioavailability can be increased, deactivation in gastric pH can be avoided, 
reduce the dose frequency and minimize side effects when compared with 
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2 
the conventional treatment. 
The approach to achieve colonic delivery of drug is by following 
methods.  
1. Coating with pH dependent polymer  
2. Timed release dosage forms  
3. Delivery system based on the metabolic activity of colonic bacteria  
4. Osmotic controlled drug delivery  
The pH dependent systems exploit the generally accepted view that 
pH of the human gastrointestinal tract increases progressively from the 
stomach (pH1-3), small intestine (6.5-7) to the colon (7-8). Most commonly 
used pH dependent coating polymers are methacrylic acid copolymers – 
Eudragit S100 which dissolve at pH 7.5. The use of Eudragit S100 
prevented drug release in the upper gastrointestinal tract and permitted 
selective drug delivery in the colon.  
The present study involves formulation, characterization and in vitro 
release study of capecitabine containing sodium alginate microspheres 
using Eudragit S100 coated capsules for the treatment of colorectal cancer 
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INTRODUCTION 
 Oral administration has been the traditionally preferred route of 
administration for most therapeutic agents and is in general the first 
avenue investigated in the discovery and development of new drug 
candidates and formulation.  
 Owing to patient acceptance convenience of administration cost 
effective manufacturing that does not required sterile processing and 
generally long product shelf life that is often dictated more by the stability 
of active drug itself rather than the formulation components. A continued 
emphasis on development oral formulations will persist.  
 Although oral delivery has become a widely accepted route of 
administration of therapeutic drugs. The gastro intestinal tract presents 
several formidable barriers to drug delivery. It is particularly for drugs that 
are susceptible to undergo degradation in the small intestine by gastric 
juice and enzymes. Therefore to achieve as well as to maintain the steady 
state drug concentration within the therapeutically effective range needed 
for treatment, it is often necessary to take this type of drug delivery system 
several times a day. This results in a significant fluctuation in drug level.  
 Recently several technical advancements have been made. They 
Chapter II Introduction 
Targeted Drug Delivery Of Capecitabine 
Microspheres For Colorectal Cancer 
 
4
have resulted in the development of new techniques for drug delivery. 
These techniques are capable of controlling the rate of drug delivery, 
sustaining the duration of therapeutic activity and / or targeting the delivery 
of drug to a tissue.  
 Sustained release is used to describe a pharmaceutical dosage 
form formulated to retard the release of a therapeutic agent such that its 
appearance in systemic circulation is delayed and / or prolonged and its 
plasma profile is sustained in duration. The onset of its pharmacologic 
action is often delayed and the duration of its therapeutic effect is 
sustained. 
 Controlled release its meaning that goes beyond the scope of 
sustained drug action. It also implies a predictability and reproducibility in 
the drug release kinetics. Which means that the release of drug 
ingredients from a controlled release drug delivery system proceeds a rate 
profile that is not only predictable kinetically but also reproducible from one 
unit to another(Chien et al.,1992).  
Site targeted drug delivery system  
 Site targeted delivery system is proposed by Ringsdorf that it is 
constructed from a non immunogenic and biodegradable polymer back 
bone having three type of attached functional group. (1) A site-specific 
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targeting moiety that leads the drug delivery to the vicinity of a target 
tissue. (2) A solubilizer that enables the drug delivery system to be 
transported to and preferentially taken up by a target tissue. (3) A drug 
moiety that is covalently bonded to the polymer back bone through a 
spacer and contains a cleavable group that can be cleaved only by 
specific enzymes at the target tissue(Edith et al.,2002; Jain et al.,2001).  
Colon target drug delivery system  
 Colon targeting is naturally of value for the topical treatment of 
diseases of colon such as Chron’s diseases, ulcerative colitis, irritable 
bowel syndrome, amoebiasis and colorectal cancer.  
 This because conventional drug delivery system for the treatment of 
colon disorders are failing as the drug do not reach the site of action in 
appropriate concentration. Thus on effective and safe therapy of these 
colonic disorders using site specific controlled release formulation is an 
important and challenging task.  
 Colon specific delivery system is also gaining importance for the 
systemic delivery of protein, peptides, oligonucleotides and vaccines. This 
is because of the unprecedented rapid development of biotechnology and 
genetic engineering resulting in the availability of peptide and protein 
drugs at a reasonable cost. These drugs are destroyed and inactivated in 
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acidic environment of the stomach and /or by pancreatic enzymes in the 
small intestine. These drugs are usually administered by parenteral route 
which is inconvenient and expensive. The same problem is also faced by 
the above mentioned colonic disorder treating drugs.  
 To achieve successful colonic delivery a drug needs to be protected 
from absorption and or the environment of the upper GIT and then be 
abruptly release into the proximal colon in a controlled manner is 
considered the optimum site for colon targeted delivery of drug. It is also 
necessary to have a good knowledge about the anatomy and physiology 
of GIT for the targeting of the drug to the colon (Edith et al., 2002;  
Jain et al.,2001,2008; Szente et al.,2007).  
Anatomy and physiology of gastrointestinal tract  
 The gastrointestinal tract is divided into three parts stomach, small 
intestine and large intestine. 
Stomach 
 Stomach is situated just below the diaphragm and liver. Its position 
however alters frequently i.e. it is pushed downwards with each inspiration 
and upward with each expiration. Its size varies according to several 
factors for some time after a meal the stomach is enlarge as food leaves 
the walls partially collapse. In adult stomach usually hold a volume of up to 
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1 liter to 1.5 liters.  
 Stomach is divided into three parts the fundus, body and pylorus. 
Fundus is the enlarged portion to the left and above the opening of 
esophagus into stomach. The body is the central part and pylorus is the 
lower portion. The curve formed by the upper right surface of the stomach 
is known as the lesser curvature and the curve formed by lower left 
surface is known as the greater curvature. The opening of stomach i.e. 
esophagus into stomach is controlled by cardiac sphincter and stomach 
into the first past of the small intestine is controlled by pyloric sphincter.  
 The stomach wall in made up of four layers serosa, longitudinal 
muscle layer, circular muscle layer, oblique muscle layer and sub mucosa 
layer. Gastric mucosa – The epithelial lining of the stomach is thrown into 
folds called rugates and marked by depression called gastric pits. 
Numerous coiled tubular type glands, gastric glands are found below the 
level of pits these glands secrete most of the gastric juice containing 
digestive enzymes and hydrochloric acid.  
Small intestine  
 The small intestine is a tube measuring about 2.5cm (1 inch) in 
diameter and 6 meter (20feet) in length. It is a coiled loop till most of the 
abdominal cavity. The small intestine consists of three divisions the 
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duodenum, the jejunum and the ileum. The duodenum is the upper most 
division it is about 25cm (10 inches) long and is shaped roughly like the 
letter C. it is the shortest part of small intestine. Then starts the jejunum at 
the point where the tube turns abruptly forward and downward. It is about 
2.5meter (8 feet). Then starts the ileum which is about 3.5 meter (12 feet) 
which is the longest part.  
 The intestinal wall is made up of outer serosa layer, longitudinal 
muscle layer, circular muscle layer and sub mucosa layer. The inner 
epithelial lining has circular plicae (fold) that have many tiny projection 
called villi. Each villus contains an arteriole, venule and lymph vessel. The 
presence of villa and microvilli increases the surface area of the small 
intestine making this organ the main site of digestion and absorption. 
Mucus secreting globlet cells are found in large number on villi and 
incrypts. The intestinal crypts serve as a site of rapid mitotic cell division.  
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Large Intestine 
Fig. 1 Large Intestine 
 
 It is the lower part of the alimentary canal which is larger in 
diameter than small intestine. Its length is about 1.5 to 1.8 meter (5 to 6 
feet). Its average diameter is about 6cm (2 ½inches) but this decreases 
towards the lower end of the tube.  
 The large intestine is divided into cecum colon and rectum. Cecum 
is the first past of 5 to 8cm length. Colon which is divided into ascending, 
transverse, descending and sigmoid colon.  
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 Ascending colon – lies in a vertical position on the right side of the 
abdomen, extending up to the lower border of the liver. The ileum joints 
the large intestine at the junction of the cecum and ascending colon, the 
place of attachment resembling the letter T.  
 Transverse colon – passes horizontally across the abdomen below 
the liver, stomach and spleen the transverse colon extends from the 
hepatic flexure to the splenic flexure the two points at which the colon 
bends on itself to form 90 degree angles.  
 The descending colon – lies in the vertical position on the left side 
of the abdomen, extending from a point below the stomach and spleen to 
the level of the iliac crest.  
 The sigmoid colon – it is the portion of the large intestine that 
courses down ward below the iliac crest is called sigmoid meaning “S”. It 
describes an S shaped curve. The lower part of the curve joint the rectum 
bends towards the left.  
Rectum  
 The last 17 to 20cm (7 or 8 inches) of the intestinal tube is called 
the rectum. The terminal inch of the rectum is called the anal canal. Its 
mucous lining is arranged in numerous vertical folds known as anal 
columns each of which contains artery and a vein.  
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 The intestinal wall consist of serosa, longitudinal muscle layer, 
circular muscle layer and sub mucosa layer. The longitudinal muscles are 
grouped into tube like strips called taeniae coli and the circular muscles 
are grouped into ring that produce pouch like haustra between them. The 
mucous glands present in sub mucosa layer which produce the lubricating 
mucus that coats the feces as they are formed.  
Blood supply to GIT  
 Arterial supply to stomach is mainly by celiac artery and to small 
intestine by superior mesenteric artery and to large intestine by superior 
and inferior mesenteric artery. Superior supplies to the caecum, ascending 
and most of transverse colon, inferior supplies to the remainder of the 
colon and proximal past of rectum. Internal iliac arteries supply to the distal 
section of the rectum and the anus.  
Function of the stomach  
 It serves as a reservoir, storing food until it can be partially digested 
and moved faster along the gastro intestinal tract. It secretes gastric juice 
containing acid and enzymes to aid in the digestion of food. Through 
contraction of its muscular coat it churns the food breaking into small 
particles and mixing them well with the gastric juice. In time, it moves the 
gastric content in to the duodenum. It secretes intrinsic factor. It produces 
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the hormones gastrin. Which helps regulate digestive functions and ghrelin 
which increases appetite. It protects the body by destroying pathogenic 
bacteria swallowed with food or with mucus from the respiratory track. It 
carries on a limited amount of absorption of certain drugs, water, alcohol 
and some short chain fatty acid found in butter or milk fat.  
Function of small intestine  
 The main function of small intestine is digestion and absorption.  
 Digestion in small intestine- The acidic chyme from the stomach 
enters into the duodenum there it mixes with the alkaline intestinal juice 
called succus entericus and the alkaline secretion from the liver and 
pancreas. The enzymes of intestinal juice are enterokinase, Erepsin 
sucrase, maltase and lactase.  
 Absorption in small intestine- The absorption of digested food 
occurs in small intestine through villi. The villi has a centeral lymphatic 
vessel called lacteal fats are absorbed into lacteal, a net work of capillaries 
surrounding the lacteal, digested products of carbohydrates and proteins 
are absorbed into these capillaries they are carried to liver by portal vein.  
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Function of Colon  
 The major function of the colon is the consolidation of the intestinal 
contents into faces by the absorption of water and electrolytes and to store 
the faces until excreted. The absorptive capacity is very high; each day 
about 200ml of fluid enters the colon through the ileocecal valve from 
which more than 90% of the fluid is absorbed. In a healthy human colon 
sodium and chloride ions are usually secreted, on average it has been 
estimated that colon contain only about 220gm of wet material equivalent 
to just 35gm of dry matter. The majority of the dry matter is bacteria.  
 Activity in the colon can be divided into segmenting and propulsive 
movement segmenting movements caused by circular muscle and causing 
the appearance of the sac like haustre. Predominate and result in mixing 
of the lumenal contents significant propulsive activity associated with 
defecation and effected by longitudinal muscle is less common and occurs 
at an average of three or four times daily (Gary et al.,2004).  
Colonic microflora  
 A large number of anaerobic and aerobic bacteria are present 
throughout the entire length of the human GIT. The upper region of the 
GIT has a very small number of bacteria and predominantly consists of 
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Gram positive facultative bacteria. The concentration of bacteria in the 
stomach is usually less than 103 colony forming units / ml (CFU/ml) and 
the most commonly isolated species are streptococci, staphylococci, 
lactobacilli and various fungi under normal conditions the microflora of the 
proximal small bowel are similar to those of the stomach. The bacterial 
concentration being 103-104 CFU/ml is found. In the distal part of the small 
intestine, a higher concentration of anaerobic bacteria is found. The lower 
ileum has a bacterial concentration of 107 - 108 CFU/ml and the distal ileum 
usually contains bacteria similar to those found in the colon. In the 
ileocecal sphincter, the bacterial concentration increase dramatically. The 
concentration of bacteria in the human colon is 1011 - 1012 CFU/ml. The 
bacterial flora of the colon is predominantly anaerobic and composed of 
more than 400 strains. The anaerobic bacteria outnumber the aerobic by a 
factor of 103 to 104. The most important anaerobic bacteria are Bacteroids, 
Bifidobacterium, Eubacterium, Peptococcus, Peptostreptococcus, Rumino 
coccus, Propionibacterium and clostridium. Important facultative bacteria 
in the large intestine are Escherichia coli and lactobacillus. The rate of 
microbial growth is greatest in the proximal area because of high 
concentration of energy source. The principle source of nutrition for the 
colonic micro organism is carbohydrate arriving in intestinal chime. A large 
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number of compound ingested orally are metabolized by gut bacteria.  
The most important metabolic reaction carried out by intestinal bacteria is  
Hydrolysis of  - Glycosides, sulphate esters, amides, 
esters, sulphamates and nitrates.  
Reduction of  - C = C, azo bond, nitro groups aldehydes,  
  ketones, alcohols and N oxides  
 Dehydroxylation, Decarboxylation, Dehalogenation of O- alkyl group 
and N alkyl group, Dehalogenation, Desamination, Heterocyclic ring 
fission, Acetylation, Esterification.  
 These metabolic actions of the micro flora are influenced by factors 
like age, gastrointestinal disease, and intake of drug and fermentation of 
dietary residues. These can lead to inactivation of drug or the 
enhancement of the action and side effects of the drugs. (Watts et al., 
1997 ; Jain et al.,2001)  
pH in the GIT  
 The pH of the GIT is subjected to both inter and intra subject 
variations. Over view of the pH of GIT.  
 Oral cavity   - 6.2 -7.4 
 Oesophagus  - 5.0 -6.0 
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 Stomach   - Fasted condition 1.5 -2.0 
     Fed condition 3.0 -5.0  
 Small intestine  - Jejunum – 5.0 -6.5 
     Ileum – 6.0 – 7.5 
 Large intestine  - Right colon - 6.4 
     Mid and left colon – 6.0 -7.0  
 Radiotelemetry has been used to measure the gastro intestinal pH 
in healthy human subject. The highest pH level 7.5 ± 0.5 were found to be 
in the terminal ileum. On entry into the colon the pH dropped to 6.4 ± 0.6. 
The pH in the mid colon was found to be 6.6 ± 0.8 and in the left colon 7.0 
± 0.7. There is a fall in pH on entry into the colon due to the presence of 
short chain fatty acids. Arising from bacterial fermentation of 
polysaccharides. It is also reduce the pH in disease eg – in a group of 7 
patients with untreated ulcerative colitis the mean pH in the proximal colon 
was 4.7 ± 0.7 where as in a group of 5 patients receiving treatment it was 
5.5 ± 0.4(Gary et al.,2004; Jain et al.,2001;Sarasija et al.,2000).  
Transit of material in the GIT  
 Gastric emptying of dosage form is highly variable and depends 
primarily on whether the subject is fed of fasted and on the  
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properties of the dosage form such as size and density. The arrival of  
an oral dosage form at the colon is determined by the rate of  
gastric emptying and the small intestinal transit time.  
The transit times of small dosage form in GIT is  
 Stomach  -  <1 (fasting) hours  
  -  >3 (Fed) hours 
 Small intestine -   3-4- hours 
 Large intestine  -  20-30 hours  
 The presence of food generally increase gastric residence and in 
some cases with regular feeding dosage form have been shown to  
reside in the stomach for period in excess of 12 hours  
(Rubinstein et al.,1991; Jain.N.K et al.,2001;Sarasija et al.,2000). Small 
intestine transit is surprisingly constant at 3- 4 hours and appears to be 
independent of the dosage form and the subjects fasted or fed state. 
Therefore a dosage form could take from a little as 4 hours to longer than 
12 hours to arrive at the colon following oral administration. However the 
movement of material through the colon is slow and tends to be highly 
variable and influenced by a number of factor such as diet, dietary fiber 
content, mobility, stress, disease and drugs. In healthy young and adult 
male dosage forms such as capsule and tablet pass through the colon in 
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approximately 20-30hours. Although the transit time of a few hours to 
more than 2 days can occur.  
 
 The effect of capsule size and density on colonic transit has been 
investigated. Capsule with a density of 1.1gm/cm3 and a volume of 0.3, 0.8 
and 1.8 cm2 and capsule with a volume of 0.8cm3 and a density of 0.7 and 
1.5 gram3 were tested. Capsule transit through the ascending colon was 
not affected by density and although there was a tendency for the transit 
rate to increase with volume this effect was not significant Dependency of 
dosage form dimension on colonic transit is demonstrated in a study which 
compare the colonic transit of 3mm, 6mm, 9mm and 12mm tablet in 2 out 
of 8 subject 6mm move a head of 3mm tablet and in all subject 9mm tablet 
move a head of 6mm tablet 20mm tablet move ahead of 6mm tablet 20mm 
tablet move ahead of 6mm tablet in only 3 of the subject. The lower 
degree of separation between 6mm and 12mm compare to 6mm and 9mm 
was explained by the fact that while the 9mm tablet has a thickness and 
diameter compare to the 6mm only the diameter of the 12mm tablet was 
change which perhaps suggests that rate of colonic transit of tablet is 
volume dependent(Rubinstein et al.,1991;1992;Edith et al.,2002).  
 The result suggested that smaller units travel through the colon 
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more slowly than larger ones. Hence additional retention of a dosage form 
within the colon could perhaps be achieved by the use of a multi 
particulate formulation rather than a large single unit thus ensuring that it 
does not pass too rapidly through the colon and be excreted before the 
entire drug has been released.  
 Dietary fiber influence greatly the colonic motility, dietary fiber 
increase fecal weight partly by retention of water and partly by increasing 
bacterial mass and reduces colonic transit times eg. Additional of 
20gm/day of brain to the diet of group of healthy subjects increased stool 
weight by 127% and reduced whole gut transit by 73 ± 24 hour to 43 ± 7 
hours. Ingestion of food has been found to stimulate colonic activity in 
what is termed the gastro colonic response the effect of eating a meal on 
the colonic transit of radio labeled tubes shows ingestion of food 
accelerates the movement of tablet through the ileocecal junction into the 
colon.  
 Diseases affect colonic transit has important implication for drug 
delivery diarrhea increase colonic transit and constipation decrease 
colonic transit. However in most disease condition transit time appears to 
remain reasonable constant (Sarasija et al.,2000;Dysseler et al.,1995).  
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Drug absorption in the GIT  
 The unionized lipid soluble drugs are readily absorbed from 
stomach and intestine. The acidic drugs are unionized in stomach so are 
absorbed from the stomach and basic drug are ionized in the stomach so 
are absorbed in the small intestine.  
 Absorption of drug from the colon is limited by a number of barriers 
in lumen itself specific and non specific drug binding can occur with dietary 
compound and products released from colonic bacteria. This drug binding 
might facilitate longer colonic residence time and hence more enzymatic or 
environmental degradation.  
 The mucus layer at the epithelial surface presents a formidable 
physical barrier because of specific and non specific drug binding. As a 
corollary to drug-mucus binding drug-mucus repulsion or expulsion could 
also act to retard the drug from reaching the epithelial surface. The space 
between the mucus layer and epithelial cell i.e. the unstirred water layer 
present another barrier to colonic absorption particularly for lipophilic 
drugs. Drug that intend to pass from the epical to basolateral surface of 
epithelial barrier must do so by passing through either colonocytes (the 
transcellular route) or between adjacent colonocytes (the paracellular 
route). Receptor mediated endocytosis and fluid – phase endocytosis 
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(pinocytosis) represent two active transport pathway which could result in 
transcellular drug delivery. Paracellular transport may be the most 
promising means of general drug absorption in the colon.  
 The positive aspect for drug absorption is the prolonged residence 
time in the colon. The factor influencing the residence time are likely to 
affect the absorption through the colon can be increase by using 
absorption enhancer (Jain et al.,2001;Chourasia.,2004) .  
Role of absorption enhancers  
 The permeability of the epithelium to drug can be modified by using 
chemical enhancers which promote absorption. The enhancer increase 
transcellular and paracellular transport by any one of the following three 
mechanisms.  
1. By disruption of inter cellular occluding junction complex formulation 
 to open the paracellular route.  
2.  By modifying epithelial permeability via denaturing membrane 
 proteins or modifying lipid protein interaction.  
3. By disrupting the integrity of lipid bilayer of colonic enterocytes.  
Adsorption enhancers used in colonic drug delivery  
a. Non steroidal anti-inflammatory agent indomethacin, salicylates.  
b. Calcium 10n chelating agents – Ethyl enediamineratra acetic acid.  
Chapter II Introduction 
Targeted Drug Delivery Of Capecitabine 
Microspheres For Colorectal Cancer 
 
22
c. Surfactants – polyoxyethylene lauryl ether  
d. Saponins  
e. Bile salt – Taurocholate, Glycocholate  
f. Fatty acid – Sodium caprate, Sodium caprylate, Sodium laurate, 
 Sodium oleate.  
g. Mixed micelles  
 Monoolein – taurochalate, oleic acid taurocholate, oleic acid – 
polyoxyethylene hydrogenated castor oil, oleic acid – glycocholate  
(Jain et al.,2001). 
Diseases in colon 
  Diseases found in colon are Chron’s diseases, ulcerative colitis, 
irritable bowel syndrome, amebiasis and colorectal cancer. 
 Colon cancer  
 Colorectal carcinoma is the second leading cancer killer and third 
most common cancer overall. The incidence of colorectal cancer is second 
for men next to lung cancer and second in women next to breast cancer. 
Colorectal cancer occurs most frequently after the age of 50; 
approximately 7% are seen in patients less than 40 years of age, about 
30-50% of patients have advanced disease when they are diagnosed.  
 Incidence of colorectal malignancies is reported to be high in USA, 
Northern and Western Europe, where as an increasing incidence is 
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observed in Asia, Africa and South America, surgery and systemic 
chemotherapy is the major therapeutic option and radiation mod of 
therapies are also of great important.  
Predisposing factors  
 Specific causes of colorectal cancer are unknown but 
environmental nutritional, genetic, familial factors and pre-existing 
diseases have been found to have some association. It has been seen 
that risk increases with consumption of animal fat and red meats while it 
decreases with consumption of fiber, vitamins ‘A’ & ‘D’, calcium and folate.  
Symptomatology  
 Adeno carcinomas of the colon and rectum grow slowly and may be 
presents for as long as five years before symptoms appears. Symptoms 
shows are change in bowel habits, fecal blood, rectal bleeding, abdominal 
pain, unexplained anemia or weight loss and fatigue.  
Pathology  
 The adenomas carcinoma sequence is established as the origin of 
nearly all colonic carcinomas from adenomas. Severe epithelial dysplasia 
is the precursor to invasive carcinoma with critical minimum size of 5mm 
with in an adenoma. The gross morphological feature of adenocarcinoma 
in the large bowel depends on the location of tumor carcinomas of 
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proximal colon tend to be large and bulky. In the more distal colon and 
rectum tumors involve a greater circumference of the bowel producing an 
annular constriction or napkin ring appearance.  
Fig. 2 Colon Cancer 
 
Classification  
 According to Maruyoma classification is based on microscopic 
criteria.  
Borrmann type I  
 Circumscribed, solitary polypoid, in part shaggy surface.  
Borrmann type II 
 Ulcerated carcinoma with elevated margins, this is the most 
common type and represents approximately two third of all colon 
carcinomas.  
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Borrmann type III  
 Ulcerative carcinoma with elevated or diffuse margins (inter mediate 
type).  
Borrmann type IV 
 Diffuse infiltrating (linitis plastic) infiltration with hardening often 
servers stenosis occurs. This occurs typically in younger patients and 
carrier a poor prognosis. Secondary colon carcinoma is frequently of this 
type.  
 Carcinomas of the large bowel are predominantly adenocarcinoma 
50% occur in the rectum and sigmoid colon and 35% in the right colon. In 
15% of tumors large lakes of mucin contain scattered collection of tumor 
cells. Cancer other than adeno carcinoma comprises less than 5% of 
malignant tumors of large bowel and includes squamous cell carcinoma 
and colacogenic or transitional cell carcinoma (Manorama et al.,1997).  
 Drugs used in colon cancer (Subramanian et al.,2002) 
 5- Fluorouracil  
 Bevacizumab  
 Irinotecan  
 Centuximab  
 Panitumumab  
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 Leucovarin  
 Oxaliplatin  
 Capecitabine   New drugs  
 
Method for targeting drug into colon  
 Colonic targeting is advantageous in treating disease of colon, oral 
delivery of proteins and peptides these is achieved by following 
method(Jain et al.,2001; Edith et al.,2002; Chourasia et al.,2003).  
1. Coating with pH dependent polymer  
2. Timed release dosage forms  
3. Delivery system based on the metabolic activity of colonic bacteria  
4. Osmotic controlled drug delivery  
1. Coating with pH dependent polymer 
 In this system drug are formulated into solid dosage form such as 
tablet, capsules, pellets and coated with pH sensitive polymer. The 
generally accepted view that pH of the human GIT increases progressively 
from the stomach (pH 1-2 which, increase to 4 during digestion) small 
intestine (pH 6-7) at the site of digestion and it increase to 7-8 in the distal 
ileum. The coating of pH sensitive polymer provides delayed release and 
protects the active drug from gastric fluid. The polymer used for colon 
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targeting however should be able to withstand the lower pH value of the 
stomach and of the proximal part of the small intestine and also be able to 
disintegrate of the neutral of slightly alkaline pH of the terminal ileum and 
preferable of the ileocecal junction. These processes distribute the drug 
throughout the large intestine and improve the potential of colon targeted 
delivery system (Chourasia et al., 2002;Sarasija et al.,2000; Edith  
et al., 2002; Jain et al.,2001;Patel et al.,2008;Meissner et al.,2007;Ibekwe 
et al.,2008;Chiu et al.,1999) widely used polymer a methacrylic resins they 
are  
¾ Eudragit L 100 (soluble at pH 6 or above)  
¾ Eudragit S 100 (soluble at pH 7 or above)  
¾ Hydroxy propyl methyl cellulose acetate Succinate  
 (Aqoat AS – HF) (Soluble at pH 7 or above)  
¾ Other commonly used polymer  
¾ Eudragit L-30D (soluble at pH 5.6) 
¾ Eudragit FS -30D (soluble at pH 6.8) 
¾ Eudragit L 100 –SS (soluble at pH 5.5) 
¾ Poly vinyl acetate phthalate (soluble at pH 5)  
¾ Hydroxypropyl methylcellulose phthalate (soluble at pH 4.5-4.8) 
¾ Hydroxy propyl methyl cellulose phthalate SD (soluble at pH 5.2) 
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¾ Hydroxyl propyl methyl cellulose phthalate SS (soluble at pH 5.4) 
¾ Cellulose acetate trimetlliate (soluble at pH 4.8)  
¾ Cellulose acetate phthalate (soluble at pH 5.0)  
 
1. Timed release dosage forms  
 This approach is based on the principle of delaying the release of 
the drug until it enter into colon, although gastric emptying tends to be 
highly variable, small intestine transit time is relatively constant. So various 
attempts are made to prevent the release of drug in the stomach for that it 
is coated with polymer which is undissolved in the gastric pH, once it have 
left the stomach the formulation arrives at the ileocecal junction about 3 to 
4 hour (Chourasia et al., 2003; Sarasija et al.,2000; Edith et al.,2002;  
Jain et al., 2001). For this purpose two types of systems are used.  
Pulsing cap system  
 This delivery system consists of a capsule, half of which is non 
disintegrating and other half enteric coated. The enteric coat dissolves on 
entering the small intestine of a hydrogel plug stoppering the non 
disintegrating part swells at a rate determined by the degree of cross 
linking. After a predetermined time (5hours) the hydrogel plug swells so 
much that is becomes ejected from the non disintegrating bottom half of 
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the capsule. There by releasing the drug. It must note that the swelling of 
the hydrogel plug is pH independent (Chourasia et al.,2003; Sarasija  
et al.,2000; Edith et al.,2002; Jain et al.,2001).  
 
Time clock  
 This delivery system has been exploited to release the drug in the 
colon. It is composed of a solid. Dosage form coated with a hydrophobic 
surfactant layer to which a water – soluble polymer is added to improve 
adhesion to the core. The outer layer redisperses in the aqueous 
environment in a time proportional to the thickness of the film and the core 
is then available for dispersion. In a study with human volunteers, it was 
shown that the lag time was independent of gastric residence time and 
hydrophobic film redispersing did not appears to be influenced by the 
presence of intestinal digestive enzymes or by mechanical action of the 
stomach (Chourasia et al.,2003; Sarasija et al., 2000; Edith et al.,2002; 
Jain et al.,2001; Patel et al.,2008).  
3 Delivery, system based on the metabolic activity of colonic bacteria 
 The colonic bacteria carry out a variety of metabolic reaction and 
hydrolysis. Different strategies were used to target to the colon based on 
Chapter II Introduction 
Targeted Drug Delivery Of Capecitabine 
Microspheres For Colorectal Cancer 
 
30
these action. The main feature of this system is their site specificity. They 
are Prodrug(Friend et al.,1984;1985; Dysseler et al.,1995;Harboe et 
al.,i989;Mladenovaka et al.,2007).  
 A well known colon specific prodrug is sulfa salazine sulfa sulazine 
is a conjugate of sulphapyridine and 5 amino salicylic acid (5-ASA) with 
the molecules linked by an azo bond (-N = N-) in the treatment of 
inflammatory bowel diseases – sulpha- salazine breaks up as 5-ASA and 
sulphapyridine by azo reductase(Dhaneshwar et al.,2007;MacNeil et 
al.,1990; Tozaki et al.,2002).  
 Another prodrug approach is glycosides glycosidases are a 
prominent group of enzymes produced by the intestinal microflora. The 
major glycosidases found in human faces are β-D galactosidase, α – L- 
arabinofuranosidase, β-D- xylo-pyranosidase and β-D–glucosidase 
prodrug of prednisolone, dexamethasone, hydrocortisone and 
fludrocortisones with β-D – galactosides and β-D-glucosides were 
prepared which are larger and hydrophilic and thus are not absorbed from 
small intestine.  
 Another approach is dextran ester prodrugs of naproxen were 
synthesized and tested for their drug release in homogenates of various 
segments of the pig GIT. Drug release was found precede 15-17 times 
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faster in caecum and colon homogenates than in homogenates of the 
small intestine. The drug release was attributed to the initial 
depolymerisation of dextran chains by dextranases of the pig colonic 
bacteria and the result and fragments served as substrates for esterases 
and other hydrolases(Jonson et al.,1966; McLeod et al.,1993;1994).  
 Anti inflammatory glucocorticoids do not process carboxylic acid 
groups and must be chemically transformed in order to reach with dextran. 
Dexamethasone and methyl prednesolone were attached to dextran using 
specific as a spacer (Chourasia et al., 2003; Sarasija et al., 2000;  
Sinha et al., 2003; Edith et al., 2002; Jain et al.,2001).  
Azo polymers  
 Poly styrene and hydroxyethylmethacrylate cross linked with 
divinylazobenzene have been used for colon delivery. Hydrophilic azo 
polymers containing different ratios of methylmethacrylate and 
hydroxethylmethacrylate (HEMA) content showed greatest susceptibility to 
colonic degradation similar result have been seen with azo containing 
polyamides and poly urethane. The swelling of the polymer in pH- 
dependent and swells in the colon to allow access to bacterial azo 
reductase enzymes (Kimura et al.,1992; Chourasia et al., 2003; Sarasija et 
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al.,2000; Sinha et al., 2003; Edith et al., 2002; Jain et al.,2001; Dhaneshar 
et al.,2007).  
Hydrogel  
 The hydrogel are used for the delivery of peptide and protein drugs. 
The hydrogel contain acidic comonomers and enzymatically degradable 
azo aromatic cross links. In the acidic pH of the stomach the gels have a 
low degree of swelling which protect the drug against degradation by 
digestive enzymes. As the gels pass down the GIT, the degree of swelling 
increases. On entering the colon the gels reach a degree of swelling which 
make the cross links accessible to enzymes (azoreductases) or mediators 
(electron carriers). The cross links are then degraded and the drug is 
released from the disintegrated gels(Bronsted et al.,1991;Chin et al.,1999; 
Vervoort et al.,1998; Chourasia et al.,2003;Sarasija et al.,2000; Sinha et 
al.,2003; Edith et al.,2002; Jain et al.,2001).  
4 Osmotic controlled drug delivery  
 The osmotic controlled drug delivery system can be used to target 
the drug locally to the colon for the treatment of disease or to achieve 
systemic absorption that is otherwise unattainable. The OROS –CT 
system can be single osmotic unit or may incorporate as many as 5-6 
push-pull units each 4mm in diameter, encapsulated within a hard gelatin 
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capsule. Each bilayer push pull unit contain an osmotic push layer and a 
drug layer both surrounded by a semi permeable membrane. An orifice is 
drilled through the membrane next to the drug layer. Immediately after the 
OROS-CT is swallowed the gelatin capsule containing the push pull units 
dissolves. Because of its drug – impermeable enteric coating each push 
pull units is prevented from absorbing water in the acidic aqueous 
environment of the stomach and hence no drug delivered. As the unit 
enter the small intestine the coating dissolve in this higher pH environment 
(pH > 7), water enters the unit causing the osmotic push co0mpartment to 
swell and concomitantly creates a flowable gel in the drug compartment 
swelling of the osmotic push compartment forces drug gel out of the orifice 
at a precisely controlled by the rate of water pass through the 
semipermiable membrane.  
 By using the above mentioned four method of colon targeting 
different formulations are made they are pellets, beads, matrix tablet, 
nanoparticles, microspheres etc. for my study microspheres has been 
selected because it can be prepared using normal lab equipments and do 
not require sophisticated instruments and can done in a less expensive 
manner (Chourasia et al.,2003).  
Microspheres  
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 Microspheres are defined as a spherical particle which contains a 
core substance. They have a characteristically free flowing powder 
consisting of proteins or synthetic polymer which is biodegradable in 
nature and ideally having a particle size less than 200µm  
(Vyas et al.,2002). 
 
Advantage of microsphere  
• Longer duration of action  
• Control of content release  
• Increase of therapeutic efficiency  
• Protection of drug  
• Reduction of toxicity  
• Biocompatibility  
• Sterilizability  
• Relative stability  
• Water solubility or dispersability  
• Targetability  
General method of preparation  
 Various technique are used and the selection is depends upon the 
nature of polymer used, amount of drug used and the duration of 
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therapy.  
Types of methods  
1. Single emulsion technique  
2. Double emulsion technique  
3. Polymerization  
a. Normal polymerization  
b. Interfacial polymerization  
4. Phase separation coacervation  
5. Spray drying and spray congealing  
6. Solvent extraction  
1.  Single emulsion technique  
 Natural polymer is prepared by this method. The polymer is 
dissolved or dispersed in an aqueous medium and is added to non 
aqueous medium (oil) to form emulsion. Then crosslinking should be 
achieved by either heat or chemical agent so formed microsphere are 
washed and dried.  
2.  Double emulsion techniques  
 Preparation involves the formation of multiple emulsion double of 
type W/O/W. It is suited for water soluble drugs, peptides, proteins 
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and vaccines. Both natural and synthetic polymers are used. The drug is 
dissolved in an aqueous medium and added to a lipophilic organic 
continuous phase stir it to form first emulsion. This is added to the 
aqueous solution of poly vinyl alcohol (PVP). This result in double 
emulsion. The emulsion is subjected to solvent removal by either solvent 
evaporation or solvent extraction then filter washed and dried.  
Chapter II Introduction 
Targeted Drug Delivery Of Capecitabine 
Microspheres For Colorectal Cancer 
 
37
3.  Polymerization techniques 
 These techniques consist of two type normal and interfacial 
polymerization 
Normal polymerization 
 Normal polymerization process is carried out by using different 
technique 
  Bulk polymerization 
  Suspension precipitation polymerization 
  Emulsion/ Miceller polymerization 
Bulk polymerization 
 Monomers or mixture of monomers along with drug and initiator is 
usually heated for polymerization. Catalyst is added to accelerate the 
reaction. The so formed polymer are molded or fragmented as 
microsphere. 
Suspension precipitate polymerization 
 Polymerization is carried out by heating the monomers or mixture of 
monomers with drug as droplets in aqueous phase, vigorous agitation and 
heating of the aqueous phase with droplets form polymerization, which is 
then washed dried to get microsphere emulsion polymerization. 
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  Differ from suspension polymer due to the presence of initiator in 
the aqueous phase which later on diffuses to the surface of the micelles or 
the emulsion globules.  
Interfacial polymerization 
 It occurs by the reaction of various monomers at the interface 
between two immiscible liquid phases. The monomers present in the two 
phases are diffuse rapidly and polymerize rapidly at the interface.  
4.  Phase separation coacervation technique  
 Phase separation method is specially designed for preparing the 
reservoir type of the system / matrix type system. The process is based on 
the principle of decreasing the solubility of the polymer in the organic 
phase to affect the formation of the polymer rich phase called the 
coacervates. The coacervates can be brought about by addition of the 
third component that are salt addition, non solvent addition, addition of in 
compatible polymer and change in pH.  
5. Spray drying and spray congealing  
 Method is based on the drying of the mist of the polymer and drug 
in the air. Removal of solvent is done by two method spray drying and 
spray congealing soldering. The rate of solvent removal is depending upon 
the temperature, pressure, solubility, the polymer, the solvent and the 
dispersion medium.  
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6.  Solvent extraction  
 Solvent extraction method is used for the removal of organic phase 
in which the microspheres is formed by using worker as solvent extraction. 
The rate of solvent removal depends on the temperature of water, ratio of 
emulsion, volume of the water and the solubility of the polymer, this 
process decreases the hardening time of the microspheres(Onishi et 
al.,2008; Chourasia et al.,2004;Paharia et al.,2007;Anande et al.,2008; 
Ziyaur et al2006).  
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REVIEW OF LITERATURE 
 Chandran. et al., (2008) designed and developed microspheres of 
indomethacin with pH and transit time dependent release properties for 
achieving targeted delivery to the colon. Microspheres containing varying 
proportions of ethyl cellulose and Eudragit (L100 or S100) either alone or 
in combination were prepared using an oil-in-oil emulsion-based solvent 
evaporation technique. microspheres with good physical properties, high 
drug loading (70-80%) and entrapment efficiency (70-85%). The lag time 
in the initial release depended on the proportion of pH-sensitive polymer 
Eudragit, while the duration of indomethacin release from microspheres 
was found to be directly proportional to proportion of the total polymer. 
Thus, a pH- and time-modulated sigmoidal release pattern could be 
observed in optimized formulations with less than 10% drug release in 
 4-6 hrs followed by controlled release extending up to 14-16 hrs. 
 Onishi et al., (2008) developed a targeted delivery system for 
inflammatory bowel disease (IBD), Eudragit L100 (EuL)-coated  
chitosan (Ch)-succinyl-prednisolone (SP) conjugate microspheres  
(Ch-SP-MS/EuL), were designed and examined in vivo for efficacy and 
toxicity. By synthesis of the conjugate by carbodiimide coupling of Ch and 
SP, conversion into microspheres (Ch-SP-MS), and coating of Ch-SP-
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MS  
with EuL. Experimental colitis was induced by instillation of 2,4,6-
trinitrobenzenesulfonic acid (TNBS) into the colon in rats. Efficacy was 
dose-dependent and the greatest in the order Ch-SP-MS/EuL>Ch-SP-
MS>prednisolone (PD) alone, and Ch-SP-MS/EuL showed excellent 
recovery of colitis states. Toxicity was the greatest in the order PD>>Ch-
SP-MS>Ch-SP-MS/EuL. Ch-SP-MS and Ch-SP-MS/EuL reduced 
significantly the thymic atrophy caused by PD. It was demonstrated that 
Ch-SP-MS/EuL enhanced effectiveness of PD and reduced toxic side 
effects of PD greatly. Also, these results established the prediction by 
previous in vitro and in vivo studies. 
 Kaur et al., (2008) developed prednisolone (PDS) beads which 
were coated sequentially with (i) innermost hydrophobic layer of 
Eudragit((R)) RS/RL, (ii) middle drug release-triggering layer of chitosan, 
organic acid and Eudragit (R)) RS/RL, and (iii) outermost enteric coating 
layer. Continuous dissolution studies were carried out in artificial simulated 
gastric fluid with and without beta-glucosidase.. Succinic acid provided the 
fastest rate of release in the colonic fluid compared to citric, tartaric or 
malic acid. The results of plasma pharmacokinetic studies in Sprague-
Dawley rats showed that the developed system provided a significant 
delay (T(max) 9.3h) in the absorption profile of PDS compared with simple 
enteric-coated (T(max) 4h) or powder (T(max) 1h) formulation that 
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was taken as proof for the colon-targeted delivery. 
 Patel et al., (2008) developed a time- and pH-dependent system for 
delivering mesalamine to the colon. The system consists of the core tablet 
of mesalamine which is compression coated with hydroxypropyl 
methylcellulose (HPMC K4M) (time-dependent factor). This is then coated 
with pH-dependent polymer Eudragit (R) L100. The simplex lattice design 
was adopted to optimize the independent variables i.e. amount of HPMC 
(X1), dextrose (X2) and polyvinyl pyrollidone (PVP) (X3) and to study their 
effect on the dependent variables i.e. lag time and time for 50% drug 
dissolution (t50). The results of the linear interactive model and graphical 
representation revealed that as the amount of HPMC increases, the lag 
time and t50 value also increases and as the amount of dextrose and PVP 
were increased the lag time and t50 value decreases. 
 Anande et al., (2008) developed cyst-targeted novel concanavalin-
A (Con-A) conjugated mucoadhesive microspheres of diloxanide furoate 
(DF) for the effective treatment of amoebiasis. Eudragit microspheres of 
DF were prepared using emulsification-solvent evaporation method. 
Formulations were characterized for particle size and size distribution,  
percetnage drug entrapment, surface morphology and in vitro drug release 
in simulated gastrointestinal (GI) fluids. Eudragit microspheres of DF were 
conjugated with Con-A. IR spectroscopy and DSC were used 
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to confirm successful conjugation of Con-A to Eudragit microspheres while 
Con-A conjugated microspheres were further characterized using the  
parameters of zeta potential, mucoadhesiveness to colonic mucosa and 
Con-A conjugation efficiency with microspheres. All the microsphere 
formulations showed good % drug entrapment (78+/-5%). Zeta potential of 
Eudragit microspheres and Con-A conjugated Eudragit microspheres were 
found to be 3.12+/-0.7mV and 16.12+/-0.5mV, respectively. Attachment of 
lectin to the Eudragit microspheres significantly increases the 
mucoadhesiveness and also controls the release of DF in simulated GI 
fluids. Gamma scintigraphy study suggested that Eudragit S100 coated 
gelatin capsule retarded the release of Con-A conjugated microspheres at 
low pH and released microspheres slowly at pH 7.4 in the colon. 
 Ibekwe et al., (2008) assessed the in vivo targeting performance of 
a novel colonic delivery coating comprising a mixture of pH-responsive 
enteric polymer (Eudragit S) and biodegradable polysaccharide (resistant 
starch) in a single layer matrix film. Tablets (radio-labelled) were film-
coated with the dual-mechanism coating and administered in a three-way 
crossover study to eight healthy volunteers (i) without food, (ii) with 
breakfast or (iii) 30 min before breakfast. The site of intestinal 
disintegration was assessed using gamma scintigraphy. The coated 
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tablets were able to resist breakdown in the stomach and small intestine. 
Consistent disintegration of the dosage form was seen at the ileocaecal 
junction/large intestine. The site of disintegration remained unaffected by 
feeding. The dual-mechanism (pH/bacterial) coating provides colon-
specificity.  
 Ravi et al., (2008) developed a novel colon targeted tablet 
formulation using natural polysaccharides such as chitosan and guar gum 
as carriers and diltiazem hydrochloride as model drug. The prepared blend 
of polymer-drug tablets were coated with two layers, inulin as an inner coat 
followed by shellac as outer coat.  In vitro studies revealed that the tablets 
coated with inulin and shellac have controlled the drug release in stomach 
and small intestinal environment and released maximum amount of drug in 
the colonic environment. Among the polymers used, chitosan was found to 
be the suitable polymer for colon targeting. The study revealed that 
polysaccharides as carriers and inulin and shellac as coating materials can 
be used effectively for colon targeting of drugs for treating local as well as 
systemic disorders. 
 Wei et al., (2007) developed colon-targeted drug delivery systems 
for 5-fluorouracil using pectin combined with ethylcellulose as a film coat 
with fluidized bed coater. Pellets (0.8-1.0 mm in diameter) containing 40% 
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5-fluorouracil and 60% microcrystalline cellulose were prepared by 
extrusion and spheronization. Film-coated pellets of  
5-fluorouracil containing various proportion of pectin and ethylcellulose 
(Surelease) were prepared and subjected to in vitro drug release. The 
results of the study show that the formulation of pectin to Surelease  
1:2, w/w is most likely to provide targeting of 5-fluorouracil for local action 
in the colon, as it released only 4.1 +/- 0.4% of the drug in the simulated 
gastric and small intestinal conditions, and it released 85.0 +/- 0.3% of 5-
fluorourail in simulated colonic fluids at the end of 24 h. Differential 
scanning calorimetric study indicated no possibility of interaction between 
5-fluorouracil and pectin or other excipients used in the coated pellets. 
 Mundargi et al., (2007) developed colon targeted drug delivery 
systems for metronidazole (MTZ). Tablets were prepared using various 
polysaccharides or indigenously developed graft copolymer of methacrylic 
acid with guar gum (GG) as a carrier. Various polysaccharides such as 
GG, xanthan gum, pectin, carrageenan, beta-cyclodextrin (CD) or 
methacrylic acid-g-guar (MAA-g-GG) gum have been selected and 
evaluated. The prepared tablets were tested in vitro for their suitability as 
colon-specific drug delivery systems. Further, in vitro release was 
performed in the dissolution media with rat caecal contents. Results 
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indicated an enhanced release when compared to formulations studied in 
dissolution media without rat caecal contents, because of microbial 
degradation or polymer solubilization. The nature of drug transport was 
found to be non-Fickian in case of uncoated formulations, whereas for the 
coated formulations, it was found to be super-Case-II. Statistical analyses 
of release data indicated that MTZ release is significantly affected by the 
nature of the polysaccharide used and enteric coating of the tablet. 
Differential scanning calorimetry indicated the presence of crystalline 
nature of drug in the formulations. 
 Dhaneshwar  et al.,  (2007) developed mutual azo prodrug of 5-
aminosalicylic acid with l-tyrosine was synthesized by coupling l-tyrosine 
with salicylic acid, for targeted drug delivery to the inflamed gut tissue in 
inflammatory bowel disease. The structure was confirmed by elemental 
analysis, IR and NMR spectroscopy. In vitro kinetic studies in rat fecal 
matter showed 87.18% release of 5-aminosalicylic acid with a half-life of 
140.28 min, following first order kinetics. Therapeutic efficacy of the carrier 
system and the mitigating effect of the azo conjugate were evaluated in 
trinitrobenzenesulfonic acid-induced experimental colitis model. 
Myeloperoxidase activity was determined by the method of Krawisz et al., 
The synthesized prodrug was found to produce comparable mitigating 
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effect as that of sulfasalazine on colitis in rats. 
 Meissner et al., (2007) developed a pH-sensitive microspheres 
loaded Enoxaparin using Eudragit P4 135F that dissolves at pH>7.2. 
Particle preparation was based on a double emulsion technique with either 
solvent extraction or evaporation. Solvent evaporation led to higher 
entrapment rates (evaporation: 70.1+/-9.9%; extraction: 46.5+/-6.4%). As 
expected, in vitro drug release was found to be strongly pH-dependent; 
LMWH was retained in microspheres at pH<6 (<20% release within 4h) 
whereas a fast drug release was obtained at pH 7.4 . These microspheres 
represent a promising tool for the selective oral delivery of heparin to the 
colon, especially interesting in the treatment of inflammatory bowel 
disease. 
    Mladenovska et al., (2007) developed chitosan-Ca-alginate 
microparticles for colon-specific delivery and controlled release of  
5- aminosalicylic  acid after  peroral administration were prepared  using 
spray drying.1H NMR, FTIR, X-ray and DSC studies indicated molecularly 
dispersed drug within the particles with  preserved stability during  
microencapsulation and in simulated in vivo drug release conditions.  
In vitro drug release studies carried out in simulated in vivo conditions in 
respect to pH, enzymatic and salt content confirmed the potential of the 
particles to release the drug in a controlled manner. Biodistribution studies 
of (131 I) -5-ASA loaded chitosan – Ca-alginate microparticles, carried 
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out within 2 days after peroral administration to Wistar male rats in which 
TNBS  colitis as induced, confirmed the dominant localization of 5-ASA in 
the colon with low systemic bioavailability. 
 
 Singh et al., (2007) developed modified-release (MR) formulation 
technologies that are claimed to provide colonic delivery for a wide array of 
therapeutic molecules. These technologies either utilize a single or a 
combination of two or more physiological characteristics of the colon, 
which includes pH, microflora (enterobacteria), transit time, and luminal 
pressure. Accordingly, these technologies may be grouped under four 
distinct classes: pH-controlled (or delayed-release) system, time-controlled 
(or time-dependent) system, microbially controlled system, and pressure-
controlled system. Among these, formulations that release drugs in 
response to colonic pH, enterobacteria, or both are most common and 
promising. 
 Szente et al., (2007) developed colon specific drug delivery 
systems for diseases having circadian rhythm. Such circadian rhythm 
release drug delivery systems are designed to provide a plasma 
concentration--time profile, which varies according to physiological need at 
different times during the dosing period, i.e., mimicking the circadian 
rhythm and severity/manifestation of gastric acid secretion (and/or 
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midnight gerd). In general four primary approaches have been proposed 
for colon targeted delivery namely pH-dependent systems, time dependent 
systems, colonic microflora activated systems and prodrugs. 
 
 Paharia et al., (2007) prepared and evaluated Eudragit-coated 
pectin microspheres for colon targeting of 5-fluorouracil (FU). Pectin 
microspheres were prepared by emulsion dehydration method. The yield 
of preparation and the encapsulation efficiencies were high for all pectin 
microspheres.  Eudragit-coating of pectin microspheres was performed by 
oil-in-oil solvent evaporation method. Pectin microspheres and Eudragit-
coated pectin microspheres were evaluated for surface morphology, 
particle size and size distribution, swellability, percentage drug 
entrapment, and in vitro drug release in simulated gastrointestinal fluids 
(SGF). The in vitro and in vivo drug release study is performed. The 
release profile of FU from Eudragit-coated pectin microspheres was  
pH dependent. In acidic medium, the release rate was much slower; 
however, the drug was released quickly at pH 7.4. It is concluded from the 
present investigation that Eudragit-coated pectin microspheres are 
promising controlled release carriers for colon-targeted delivery of FU. 
 Yongmei Xu et al., (2007) prepared alginate-chitosan(ALG-CS) 
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blend gel beads based on Ca2+or dual cross linking with various 
proportions of alginate and its chitosan. The dual crosslinkage effectively 
promoted the stability of beads under gastro intestinal tract conditions. The 
sustained release profiles of single and dual crosslinked gel beads loaded 
bovaine serum albumin (BSA), a model protein drug, were investigated in 
simulated gastric fluid(SGF), simulated intestinal fluid (SIF) and simulated 
colonic fluid (SCF). The dual crosslinked beads incubated in 
gastrointestinal tract conditions, the BSA cumulative release of ALG-CS 
mass ratios 9:1,7:3 and 5:5 respectively 2.35,1.96,1.76%(in SGF4h) 
82.86%, 78.83,52.91% (in SIF 3h) and 97.84,96.81,87.26%(in SCF 3h), 
which suggested that the dual crosslinked beads have potential small 
intestine or colon site-specific drug delivery property. 
 Ziyaur et al., (2006) prepared and evaluated the colon-specific 
microspheres of 5fluorouracil for the treatment of colon cancer. Core 
microspheres of alginate were prepared by the modified emulsification 
method in liquid paraffin and by cross-linking with calcium chloride. The 
core microspheres were coated with Eudragit S-100 by the solvent 
evaporation technique to prevent drug release in the stomach and small 
intestine. The microspheres were characterized by shape, size, surface 
morphology, size distribution, incorporation efficiency, and in vitro drug 
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release studies. The core microspheres sustained the drug release for 10 
hours. The release studies of coated microspheres were performed in a 
pH progression medium mimicking the conditions of the gastrointestinal 
tract. Release was sustained for up to 20 hours in formulations with core 
microspheres to a Eudragit S-100 coat   
 
 Watts et al., (2005) designed site-specific delivery of drugs in the 
gastrointestinal (GI) tract and, in particular, targeted release into the 
colonic region. A key area of application is the delivery of therapeutic 
agents for local treatment of lower GI diseases. The technology is based 
on the application of pH-sensitive coatings onto injection-moulded starch 
capsules. An extensive body of clinical data has been generated showing 
reliable in vivo performance of the capsules. In gamma-scintigraphy 
studies around 90% of targit capsules (n = 84) delivered their contents to 
the target site of the terminal ileum and colon. TARGIT-based products are 
in active clinical development for the treatment of conditions including 
inflammatory bowel diseases. 
 Varshosaz et al., (2005) developed mesalazine (5-ASA) chitosan 
microspheres, colon-specific delivery system for crohn’s disease and 
ulcerative-colitis. Coated chitosan microspheres were used for this 
purpose by an emulsion-solvent evaporation technique based on a 
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multiple w/o/w emulsion. Release of 5-ASA from microspheres was 
studied in different pHs 1.2,7.4,6.8 and 6.8 and in the presence of caecal 
contents of rat. Microspheres of chitosan with medium molecular weight 
and 1:1 core/coat that showed the greatest release of drug (near 80%) in 
the presence of caecal secretions with a zero-order mechanism, near zero 
percent in pH 1.2 after 2h, max 20% in pH 7.4 after 3h and near 60% in pH 
6.8 after 8h seen suitable for site- specific delivery of 5 ASA in vitro. 
    Jain et al., (2005) developed  colon specific delivery system 
bearing flurbiprofen using various azo-aromatic polymers and pH-sensitive 
polymers are discussed In vitro dissolution studies showed that 
flurbiprofen bearing hard gelatin capsules, coated with these polymers 
released drug only in gastro intestinal fluid containing human fecal 
suspension, at pH 7.5. In vivo studies revealed that azo aromatic and pH-
sensitive polymer coating disintegrate only in colon following 10h of oral 
administration. Hence these polymers can be successfully used to deliver 
drug at the colon. 
  Chourasia et al., (2004) developed a novel formulation consisting 
of cross-linked microspheres of guar gum has been investigated for colon-
targeted delivery of metronidazole. An emulsification method involving the 
dispersion of aqueous solution of guar gum in castor oil was used to 
prepare spherical microspheres. Shape and surface morphology of 
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the microspheres were examined using scanning electron microscopy. 
Particle size of the microspheres was determined using laser diffraction 
particle size analyzer. In vitro release rate studies were carried out in 
simulated colonic fluid (SCF) with and without in the presence of rat cecal 
contents, which showed improved drug release. A marked improvement in 
the drug release was observed in presence of cecal matter obtained after 
induction when compared to those without induction. In vitro release 
studies exhibited 31.23+/-1.49% drug release in 24 h in dissolution 
medium without rat cecal matter. However, the incorporation of 4% w/v 
cecal matter obtained after 6 days of enzymes induction increased the 
drug release to 96.24+/-4.77%. 
 Chourasia et al., (2004) developed a multiparticulate system 
combining pH-sensitive property and specific biodegradability for colon-
targeted delivery of metronidazole has been investigated. The 
multiparticulate system was prepared by coating cross-linked chitosan 
microspheres exploiting Eudragit L-100 and S-100 as pH-sensitive 
polymers. In vitro drug-release studies were performed in conditions 
simulating stomach-to-colon transit in presence and absence of rat caecal 
contents. By coating the microspheres with Eudragit  
pH-dependant release profiles were obtained. No release was observed at 
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acidic pH; however, when it reached the pH where Eudragit starts 
solublizing there was continuous release of drug from the formulation. 
Further, the release of drug was found to be higher in the presence of rat 
caecal contents, indicating the susceptibility of chitosan matrix to colonic 
enzymes released from rat caecal contents. 
  Momin et al., (2004) developed colon targeted drug delivery 
systems for sennosides using guar gum as a carrier. Matrix tablets 
containing various proportions of guar gum were prepared by wet 
granulation technique using starch paste as a binder. The tablets were 
evaluated for content uniformity and in vitro drug release study as per BP 
method. The matrix tablets containing 50% of guar gum were found to be 
suitable for targeting of sennosides for local action in the colon. Compared 
to tablets having 30% and 40% of guar gum, those with 50% guar gum 
fewer amounts (5-8%) of drug release in upper GIT. These tablets with 
50% guar gum released 43% and 96% sennosides with and without rat 
caecal fluids. This suggests the susceptibility of matrix to the colonic micro 
flora. When hydroxy propyl methylcellulose phthalate (10%) was used as a 
coat material on the matrix tablets, the initial loss of 5-8% sennosides in 
stomach could be completely averted. The results of our study indicates 
that matrix tablets containing 50% guar gum and coated with 10% hydroxy 
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propyl methylcellulose phthalate are most suitable for drugs like 
sennosides which are mainly active in the lower GIT. 
 El-Gibaly et al., (2002) developed ketoprofen-loaded Zn-pectinate 
gel (ZPG) microparticles together with pectin/dextran mixtures in a tablet 
form, has been investigated, in vitro, using conditions chosen to simulate 
the pH and times likely to be encountered during transit to the colon. The 
results obtained implied that the release of ketoprofen from ZPG 
microparticles was greatly extended with the pectinate microparticles. The 
results also demonstrated that the untableted ZPG microparticles exhibited 
drug release profiles which were able to retard the release of ketoprofen in 
S.I.F. (pH 7.4) to be 5.28-37.82 times (depending on formulation 
parameters), lower than the conventional calcium pectinate beads. 
Therefore, this approach suggests that ZPG microparticles and their 
modified-release formulations are promising as useful controlled-release 
carriers for colon-targeted delivery of drugs. 
 Rasmane et al., (2000)  developed  theophylline pellets coated with 
Eudragit NE30D aqueous dispersion, containing various pectin 
HM/Eudragit RL30D ionic complexes’ using an uni-glatt fluidized-bed 
apparatus . Dissolution studies were then carried out on the coated pellets 
at pH 6.0, in absence and in presence of commercial pectinolytic 
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enzymes. The theophylline release from the coated pellets as slower in 
presence of the pectinolytic enzymes when the pectin content of the 
complexes is higher than 20.0%w/w. On the other hand, the effect of the 
enzymes induced an increase of the theophylline release when the pectin 
HM content of the coating ranged between 10.0 and 15.0% /w (related to 
the Eudragit RL).   
 Ishibashi et al., (1998) scintigraphic study was to provide "proof of 
concept" for a novel capsule-type colonic delivery system (Colon-Targeted 
Delivery Capsule) in healthy volunteers. The human data validates the 
design concept behind the release mechanism, in that capsule 
disintegration, and hence drug release, did not start until 5 h after gastric 
emptying, irrespective of whether the product was administered to fasted 
or fed subjects. However, the potential for prolonged gastric residence for 
large enteric coated products intended for intestinal targeting was also 
observed; overall, the study provides a focus for subsequent product 
development and highlights the role of scintigraphy in dynamically 
visualizing the drug delivery process. 
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DRUG PROFILE 
CAPECITABINE  
 Capecitabine is a new anticancer therapy for oral administration. It 
is a fluoro pyrimidine which is converted into 5-fluoro uracil once inside the 
tumour. The drug takes advantage of the higher thymidine phosphorylase 
activity in malignant tissue. Its activity and safety had already been tested 
in two large phase –III trials, where it provided to be superior to 5-fluoro 
uracil / leucovorin  
 Molecular formula  –  C15H22FN3O6 
 Molecular weight  –  359.35 
 Melting point  –  110 - 121°C 
Chemical Name 
 1 – (5Deoxy β – D – ribofuranosyl – 5 -  fluoro – 1,2 – dihydro – 2 – 
oxo – 4 – pyrimidimyl) – Carbamic acid pentyl ester. 
Solubility 
 Soluble in dichloromethane and methanol, Slightly soluble in water. 
Composition 
 C - 50.14% 
 H - 6.17% 
 F - 5.29% 
 N - 11.69% 
 O - 26.71% 
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Chemical Structure 
 
 
 
  
 
 
 
 
 
BIO ACTIVATION  
 Capecitabine is readily absorbed from the gastro intestinal tract. In 
the liver, a 60 K Da Carboxylestesterase hydrolyzes much of the 6 
compound to 5 – deoxy – 5- fluorocyticline [5-DFCR] Cytidine deaminase, 
an enzyme found in most tissues, including tumors, subsequently converts 
5-DFLT to 5- deoxy – 5- fluorouridine [5-DFUR] . The enzyme thymidine 
phosphorylase then hydrolyzes 5 – DFUR to the active drug 5 fluoro uracil. 
Human carcinomas express these enzymes in higher concentrations than 
surrounding normal tissues. 
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 Both normal & tumor cell metabolize 5-Fu to 5-fluoro-2-
deoxyyuridine mono pho 5phate & 5-flurousidine triphosphate these 
metabolites cause cell injury by two different mechanisms. First  
5 – fluoro – 2 - deoxyuridine monophosphate & the folate cofactor  
N5-10 – methylenetetrahydrofolate find to thymidylate synthase (T5) to form 
a covalently bound ternary complex. This finding inhibits the formation of 
thymidylate from 2-deoxyuridylate Thymidylate is the necessary precursor 
of thymidine triphosphate which is essential for the synthesis of DNA, so 
that a deficiency of this compound can inhibit cell division second, nuclear 
transcriptional enzymes can mistakenly incorporate FUTP in place of 
uridine triphosphate during the synthesis of RNA. This metabolic error can 
interfere with RNA processing & protein synthesis. 
PHARMACOKINETICS 
 Capecitabine is rapidly & almost completely absorbed unchanged 
from the gastrointestinal tract, food decrease rate and extent of absorption 
but the clinical significance is unclear. Capecitabine is recommended to be 
taken with food because its efficacy & safety are based on studies when it 
was given within 30 min after a meal. It takes 1.5 hours to attain peak 
plasma concentration 60% of the drug is bound to plasma proteins. It is 
metabolized in the liver to 5 – deoxy-5- fluorocytidine [5-DFCR] and then 
to 5-deoxy -5 fluorouridine [5-DFUR] in liver and tumour tissues. Where it 
interfere in the synthesis of DNA & RNA processing & protein synthesis. It 
is mainly excreted through urine (96%). 
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USES 
 Apart from colorectal carcinoma it is also used in breast cancer and 
pancreatic cancer.  
DOSAGE 
 Capecitabine is administrated orally – 1250mg/m2 [range 313 – 
1250 mg/m2] twice a day for 14 consecutive days starting on day 1 [total 
dose per cycle 35000 mg/2 [range 8764-35000mg/m2] followed by a  
1 week rest period given as 3 week cycles. 
ADVERSE EFFECT  
 The most common adverse effect of capecitabine are diarrhea, 
nausea, vomiting, abdominal pain, Stomatitis, anemia, Lymphopenia, 
dermatitis, bronchospasm fatigue, hyperbilirubinemia, pyrexia, 
dehydration. (AAHFS Drug introduction et al., 2004; Subramanian  
et al., 2002). 
Chapter V Polymer Profile 
Targeted Drug  Delivery  Of 
Capecitabine  Microspheres For 
Colorectal  Cancer 
 
60
POLYMER PROFILE 
Sodium alginate  
 
 
  
 
 
 Sodium alginate is water soluble salt of alginic acid which is a 
polysaccharide extracted from marine brown algae. It contains two uronic 
acids β- D – Mannuronic acid (M) and α – L – glucouronic acid (G) and it is 
composed of homopolymeric block MM or GG and blocks with an 
alternating sequence (MG block). Many grades of sodium alginate are 
available and are selected depending upon the purpose, e.g. high  
L – glucouronic acid content gives high gel strength. Most of the alginic 
acid consists of the homopolymeric block of D- Mannuronic acid and  
L- glucouronic acid.  
 Sodium Alginate is a white or slightly yellow powder freely soluble in 
hot or cold water, a four percent (4%) solution giving a thick viscous fluid. 
The solution is not coagulated by heat and does not set to jelly on 
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cooling. It can be made to gel by converting it partly into a calcium salt by 
adding a  
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small proportion of calcium chloride alginate microsphere are prepared by 
suspending the drug or protein in sodium alginate solution and spraying 
this solution into 1.3% W/U buffered calcium chloride to form cross linked 
micro capsules.  
 Another method is modified emulsion method in this the drug is 
suspended in sodium alginate solution and add this suspension into 
primary emulsion (liquid paraffin heavy with span 80) drop wise to form 
W/o type of emulsion to this add calcium chloride drop wise form cross 
linked microspheres.  
Function  
 Used as stabilizing agent, suspending agent, tablet and capsule 
disintegrant, tablet binder, viscosity increasing agent.  
Application in pharmaceutical formulation  
 Sodium alginate is used in variety of oral and topical 
pharmaceutical formulation.  
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EUDRAGIT S 100 
 Eudragit S 100 is a anionic copolymers based on methacrylic acid 
and methyl methacrylate. The ratio of the free carboxyl groups to the ester 
groups is approximately. 1:2  in eudragit S -100. The average molecular 
weight is 135,000. 
Structure 
 
 
 
 
Description 
 White powders with a faint characteristic odour 
Solubility 
 1 g of Eudragit s -100 is dissolves in 7 g methanol, ethanol, in 
aqueous isopropyl alcohol and acetone (containing approx. 3 % water), as 
well  as in 1 N sodium hydroxide to give clear to slightly cloudy solutions. 
Insoluble in ethyl acetate,  methylene chloride, petroleum ether  and water. 
Identity testing 
Assay 
 The assay is performed according to” Potentiometric titration" 
approximately. 0.5 g eudragit S-100 are dissolved in 60 ml isopropyl 
CH2 C CH2 C
CH2
C O
OH 
C O
CH3
CH3
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alcohol and 40 ml water with stirring for 30 to 60 minutes at 50 °C. 
 
Sodium hydroxide (NaOH) 0.5 N is used as the titrant. Under the same 
conditions, a blank value is determined. 1 ml 0.5 N NaOH corresponds to 
43.045 mg methacrylic acid units. 
Viscosity / Apparent viscosity 
 Eudragit S-100: 50 - 200 mPa. The viscosity of the Test  
solution is determined by means of a Brookfield viscometer (spindle 1 /30 
rpm / 20 °C). 
Refractive index 
 1.390 - 1.395.  
Relative density 
  0.831 - 0.852.  
Purity 
Sulphated ash / Residue on ignition 
 Max. 0.1 % 
Heavy metals 
 Max. 20 ppm 
Arsenic 
 Max. 2 ppm  
Storage 
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 Protect from warm temperatures protect against 
moisture(Raymondetal.,1992;Internet:WWW.roehm.com). 
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METHODOLOGY 
MATERIALS USED 
Pure Drug 
1. CAPECITABINE   -  Dr Reddy`s Labs, Medak Dist:, A.P., 
India (gift sample) 
Polymer & Excipient 
2. Sodium Alginate  -  Loba Chemie Pvt Ltd Mumbai 
3. Eudragit S 100  -  Rohm pharma .,Germany (gift sample) 
4. Liquid paraffin heavy -   Loba Chemie Pvt Ltd Mumbai 
5. Tween 80  -  Loba Chemie Pvt Ltd Mumbai 
6. Span 80  -  Loba Chemie Pvt Ltd Mumbai 
7. Petroleum ether -  Qualigens fine chemicals Mmbai 
8. Methanol -  Loba Chemie Pvt Ltd Mumbai 
9. Dichloromethane  -  Loba Chemie Pvt Ltd Mumbai 
10. Dibutyl phthalate  -  Loba Chemie Pvt Ltd Mumbai 
11. Distilled water  -   Ultra pure Pvt Ltd Coimbatore  
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INSTRUMENTS USED 
1. Mechanical stirrer   -  Universal motors Mumbai 
2. Vacuum dessicator 
3. Magnetic stirrer 2MLH    -  REMI Instruments, Vasai. 
4. Dissolution rate test 
      apparatus USP XXII   -  Dolphin, Mumbai 
5. pH meter LI-120   -  Elico, Mumbai 
6. Electronic weighing  
 balance ELB-300   -  Shimadzu, Japan.  
 
7. High Sensitive  
 digital Balance HR 200    -  AND Japan 
 
7. Scanning Electron Microscope- Jeol Jsm , Japan 
 6400 
 
8. UV- Visible  
 Spectrophotometer  
 UV-1650PC   -  SHIMADZU, Japan. 
9. Infrared Spectrophotometer  
 FTIR-8400S  -  SHIMADZU, Japan 
 
 
10. KBr PRESS model M-15   -  Techno search instruments    
Chennai 
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PREFORMULATION STUDIES  
Infrared (IR) absorption spectroscope 
 To investigate any possible interaction between the drug and the 
polymer, the IR spectra of pure drug capecitabine, its physical mixture 
sodium alginate were carried out using Infrared spectrophotometer  
FTIR-8400S Shimadzu (TOKY0 JAPAN). The sample were prepared as 
KBr disks compressed under a pressure 8 ton/nm2 and the wave length 
selected ranged   between 400-4000cm-1. 
 The IR spectrum of the physical mixture was compared with those 
of pure drug and polymer to detect any appearance or disappearance of 
peaks. 
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Fig.3 IR SPECTRUM OF CAPECITABINE 
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Fig. 4   IR SPECTRUM OF SODIUM ALGINATE 
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Fig.5   IR SPECTRUM OF PHYSICAL MIXTURE 
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PREPARATION OF STANDARD GRAPH OF CAPECITABINE 
 An accurately weighed quantity of 100mg Capecitabine was 
transferred into a 100ml standard flask and volume was made up to the 
mark using Phosphate buffer of pH 7.6. 
 From the primary stock solution 2ml was transferred to 100 ml 
volumetric flask and diluted upto the mark using Phosphate buffer of pH 
7.6.The concentration of the solution will be 20µg/ml. Various 
concentrations 2µg,4µg, 6µg, 8µg, 10µg, 12µg, 14µg, 16µg, 18µg and 
20µg were prepared by diluting 1ml, 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 9ml 
and 10ml  of the stock solution to 10ml using  buffer of pH 7.6 respectively. 
The absorbance was noted at 239nm using UV/Vis Spectrophotometer.  
 Similarly the various standard graphs of capecitabine were 
prepared in  0.1 N HCl pH 1.2 and with phosphate buffer of pH 6.8..  
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Table 1 : Standard graph of capecitabine at pH 7.6 
Concentrations (µg/ml) Absorbance (239nm) 
2 0.07886 
4 0.14136 
6 0.23059 
8 0.31946 
10 0.37915 
12 0.45410 
14 0.53394 
16 0.61365 
18 0.68933 
20 0.76611 
 
Fig.6 : Standard graph of capecitabine at pH 7.6 
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Table 2 : Standard graph of capecitabine at pH 6.8 
Concentrations (µg/ml) Absorbance (239nm) 
2 0.07918 
4 0.16136 
6 0.25595 
8 0.34093 
10 0.44078 
12 0.54246 
14 0.63000 
16 0.71958 
18 0.82859 
20 0.91366 
 
Fig.7: Standard graph of capecitabine at pH 6.8 
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Table 3: Standard graph of capecitabine at pH 1.2 
Concentrations (µg/ml) Absorbance (239nm) 
2 0.06763 
4 0.17236 
6 0.25879 
8 0.32554 
10 0.44726 
12 0.51013 
14 0.60339 
16 0.70144 
18 0.77563 
20 0.83484 
 
Fig. 8 : Standard graph of capecitabine at pH 1.2 
 
 
Chapter VI                  
Methodology 
Targeted Drug Delivery  Of Capecitabine  
Microspheres For Colorectal  Cancer 
 
75
 
PREPARATION OF SODIUM ALGINATE MICROSPHERES 
CONTAINING CAPECITABINE 
 
 Sodium alginate microspheres containing capecitabine were 
prepared by using single emulsion technique.  Heavy liquid paraffin was 
used as the external phase and aqueous solution of Sodium alginate was 
used as dispersed phase. 
Procedure 
 Drug and polymer were weighed as per the table (Table -2) and 
mixed well to make a homogeneous drug polymer solution. 
 The 10ml of the drug polymer solution is added drop wise into 30ml 
of heavy liquid paraffin containing 2 to 4 drop (0.2%) span 80 and stirred 
for 90 minutes. Different concentrations of calcium chloride 6ml as per the 
table was added to the emulsion and stirred for 15 minutes.  The prepared 
microspheres were washed with petroleum ether for several times and 
filtered and dried (ziyaur et al., 2006;Asha et al.,2006). 
Preparation of eudragit –S- 100 coated gelatin capsule 
 Dipping method is used for coating the microspheres containing 
hard gelatin capsule.  Hard gelatin capsule (size No 1) was taken, cap and 
body is separated.  Each part is dipped into 10% w/v Eudragit S- 100 
solution in the methanol and dichloro methane mixture (1:4) along with 2% 
v/v dibutyl phthalate as plasticizer, for 6 times with an interval of 3hrs.  The 
coated body is filled with accurate amount of microspheres and sealed 
(Ishibashi et al.,1998;Jain et al.,2005;Ziyaur et al.,2006) 
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Table 4 : Various formulation of capecitabine containing alginate 
microspheres 
 
Sl 
No. 
Formulation 
Code 
Drug used in 
Formulation 
(mgs) 
Volume of 
Polymer used 
in Formulation 
(ml) 
Drug : 
Polymer 
Ratio 
Percentage 
of cross 
linking 
agent 
1 FA1 125 3.125 (4%) 1:1 2  (6ml) 
2 FA2 125 6.25  (4%) 1:2 2  (6ml) 
3 FA3 125 3.125 (4%) 1:1 5  (6ml) 
4 FA4 125 6.25  (4%) 1:2 5  (6ml) 
5 FB1 125 2.5 (5%) 1:1 2  (6ml) 
6 FB2 125 5  (5%) 1:2 2  (6ml) 
7 FB3 125 2.5 (5%) 1:1 5  (6ml) 
8 FB4 125 5  (5%) 1:2 5  (6ml) 
9 FC1 125 2.08 (6%) 1:1 2  (6ml) 
10 FC2 125 4.17 (6%) 1:2 2  (6ml) 
11 FC3 125 2.08  (6%) 1:1 5  (6ml) 
12 FC4 125 4.17  (6%) 1:2 5  (6ml) 
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DETERMINATION OF SIZE AND SHAPE OF MICRO PARTICLES BY 
SCANNING ELECTRON MICROSCOPE 
 The surface morphology and internal texture of Capecitabine micro 
particles were observed by a scanning electron microscope. Scanning 
electron microscope photographs were taken on JSM 6400 Scanning 
electron microscope at 3K magnification at room temperature. Before 
scanning the micro particles were sputtered with gold to make the surface 
conductive. The Fig. 9  shows that the particles are spherical enough and 
having rough surface.   
Fig. 9 SEM photograph 
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DETERMINATION OF PARTICLE SIZE OF MICROPARTICLES BY 
OPTICAL MICROSCOPIC METHOD 
 Clean the microscope and focus for bright light.  Eye piece micro 
meter is fixed and calibrated using stage micrometer.  Few drops of 
samples is mounted on the clean glass slide minimum of 200 particle is 
counted and the mean size is calculated using the formula. 
 Arithmetic Mean = Σnd/ Σn 
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Table 5 : Particle size distribution of formulations FA1,FA2,FA3,FA4 
FORMULATION 
CODE 
PARTICLE 
SIZE 
RANGE(µM) 
MEAN 
DIAMETER 
(µm)(d) 
NUMBER OF 
PARTICLES(n) nxd 
0 – 10 5 43 215 
10 – 20 15 108 1620
20 – 30 25 32 800 
FA1 
30 – 40 35 17 595 
0 – 10 5 53 265 
10 – 20 15 107 1605
20 – 30 25 30 750 
FA2 
30 – 40 35 10 350 
0 – 10 5 32 160 
10 – 20 15 108 1620
20 – 30 25 40 1000
FA3 
30 – 40 35 20 700 
0 – 10 5 61 305 
10 – 20 15 79 1185
20 – 30 25 43 1075
FA4 
30 – 40 35 17 595 
The Arithmetic Mean of particle size 
FA1 = 16.15µm, FA2 = 14.86 µm, FA3 = 17.4 µm, FA4 = 15.8 µm 
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Fig. 10  Particle size distribution of formulations FA1,FA2,FA3,FA4 
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Table 6: Particle size distribution of formulations FB1, FB2, FB3, FB4 
FORMULATION 
CODE 
PARTICLE 
SIZE 
RANGE 
(µM) 
MEAN 
DIAMETER 
(µm)(d) 
NUMBER OF 
PARTICLES 
(n) 
nxd 
0 – 10 5 57 285 
10 – 20 15 83 1245 
20 – 30 25 32 800 
FB1 
30 – 40 35 28 980 
0 – 10 5 49 245 
10 – 20 15 83 1245 
20 – 30 25 30 750 
FB2 
30 – 40 35 38 1330 
0 – 10 5 23 115 
10 – 20 15 76 1140 
20 – 30 25 47 1175 
FB3 
30 – 40 35 54 1890 
0 – 10 5 17 85 
10 – 20 15 73 1095 
20 – 30 25 50 1250 
FB4 
30 – 40 35 60 2100 
The Arithmetic Mean of particle size 
FB1 = 16.55 µm, FB2 = 14.86 µm, FB3 = 21.6µm, FB4 = 22.65 
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Fig. 11 : Particle size distribution of formulations FB1, FB2, FB3, FB4 
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Table 7: Particle size distribution of  formulations FC1,FC2, FC3, FC4 
FORMULATION 
CODE 
PARTICLE 
SIZE 
RANGE 
(µM) 
MEAN 
DIAMETER 
(µm)(d) 
NUMBER OF 
PARTICLES 
(n) 
nxd 
0 – 10 5 11 55 
10 – 20 15 93 1395 
20 – 30 25 63 1575 
FC1 
30 – 40 35 33 1155 
0 – 10 5 16 80 
10 – 20 15 79 1185 
20 – 30 25 60 1500 
FC2 
30 – 40 35 45 1575 
0 – 10 5 11 55 
10 – 20 15 70 1050 
20 – 30 25 68 1700 
FC3 
30 – 40 35 51 1785 
0 – 10 5 8 40 
10 – 20 15 54 810 
20 – 30 25 60 1500 
FC4 
30 – 40 35 78 2730 
The Arithmetic Mean of particle size 
FC1 = 20.9 µm, FC2 = 21.7 µm, FC3 = 22.95 µm, FC4 = 25.4 µm 
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Fig. 12 :  Particle size distribution of  formulations FC1,FC2, FC3, FC4 
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ENTRAPMENT  EFFICIENCY 
 25mg of drug loaded core microspheres was weighed and washed 
with 10ml of phosphate buffer of pH 6.8 to remove the surface – 
associated drug.  Then microspheres were kept in phosphate buffer of 
pH 7.6 for digestion for 24hrs and sonicated for 1 hr at room temperature.  
From that 1ml of sample is withdrawn and diluted 1000 times using 
phosphate buffer pH 7.6 and quantified spectrophotometrically at 239nm 
(Ziyaur et al.,2006). 
 Entrapment efficiency is determined by using the formula. 
  Practical yield from graph 
 % entrapment  = 100
loadedamount  Initial
graph  from yieldPartical X  
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Table 8 : Percentage entrapment efficiency of formulations 
S.No. Formulation Code 
Practical 
Yield in mg 
Absorbance 
in nm 
Graph 
yield in 
µgm 
Percentage
entrapped 
efficiency 
1 FA1 170 0.412 10.8 58.75±0.89
2 FA2 228.5 0.417 10.9 79.7±0.75 
3 FA3 299 0.113 3 28.7±0.52 
4 FA4 253.6 0.376 9.7 78.73±1.09
5 FB1 230 0.175 4.6 33.92±0.23
6 FB2 216 0.262 6.9 47.7±0.57 
7 FB3 179 0.135 3.5 20.05±0.42
8 FB4 167 0.286 7.5 40.06±0.41
9 FC1 271 0.062 1.7 14.74±0.24
10 FC2 367.1 0.107 2.8 32.9±o.31 
11 FC3 367.2 0.056 1.5 17.62±o.82
12 FC4 295.2 0.072 1.9 17.95±0.13
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Fig. 13 Percentage entrapment efficiency of formulations 
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IN VITRO RELEASE STUDIES 
 In vitro drug release was studied using temperature controlled 
magnetic stirrer, with 10ml of dissolution medium maintained at 37°C at 60 
rpm. 
Procedure 
 5mg of core microspheres were suspended in 10ml of phosphate 
buffer (pH 7.6) containing 0.02% w/v tween 80.  1ml of sample were 
withdrawn at specified time intervals 15min, 30min, 45min, 60min, 75min, 
90min, 105min, and 120min replaced with 1ml fresh phosphate buffer pH 
7.6.   Dissolution sample is further diluted to 100 times using phosphate 
buffer pH 7.6 solution and quantified spectrophotometrically at 
239nm(Ziyaur et al.,2006). 
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Table  9: In vitro dissolution profile of 4% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
formulations FA1,FA2,FA3,FA4 
 
Percentage of release  Time in 
minute FAI FA2 FA3 FA4 
15 3.54±0.26 44.61±0.11 38.10±0.18 27.54±0.25 
30 37.25±0.18 50.13±0.19 49.14±0.09 47.89±0.21 
45 38.9±0.41 57.77±0.43 58.51±0.20 51.25±0.12 
60 47.88±0.36 58.50±0.29 67.77±0.31 67.11±0.23 
75 49.78±0.21 64.35±0.31 78.12±0.73 69.39±0.15 
90 50.05±0.45 67.77±0.52 84.13±0.63 78.55±0.12 
105 54.01±0.75 86.29±0.34 87±1.03 79.81±0.19 
120 54.41±0.32 87.11±0.78 92.02±1.23 81.91±0.01 
Fig.14: In vitro dissolution profile of 4% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
formulations FA1,FA2,FA3,FA4 
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Table 10: In vitro dissolution profile of 5% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
formulations FB1,FB2,FB3,FB4 
 
Percentage of release  Time in 
minute FBI FB2 FB3 FB4 
15 15.62± 0.27 48.58±0.18 35.18±0.23 37.05±0.21 
30 18.81±0.22 66.98±0.19 36.33±0.18 37.43±0.22 
45 20.54±-0.19 68.19±0.28 39.18±0.19 47.16±0.18 
60 24.88±0.20 69.93±0.13 46.34±0.20 48.28±0.16 
75 27.78±1.19 78.76±0.18 52.06±0.12 52.4±0.18 
90 30.09±1.20 80.97±0.17 55.21±0.13 52.8±0.16 
105 32.12±0.22 85.39±0.19 60.64±0.19 52.52±0.20 
120 36.46±0.16 86.12±0.14 61.24±0.20 68.11±0.29 
Fig.15: In vitro dissolution profile of 5% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
formulations FB1, FB2, FB3,FB4 
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Table 11: In vitro dissolution profile of 5% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
formulations FC1, FC2, FC3, FC4 
 
Percentage of release  Time in 
minute FCI FC2 FC3 FC4 
15 7.36±0.18 14.67±0.11 25.24±0.18 14.16±0.18 
30 12.99±0.13 23.48±0.12 29.94±0.17 16.52±0.17 
45 28.58±0.13 31.12±0.18 35.81±0.16 21.71±0.15 
60 32.48±0.11 41.10±0.19 47.56±0.15 31.16±0.21 
75 54.57±0.19 48.15±0.14 58.72±0.21 39.8±0.22 
90 59.29±0.20 59.30±0.14 65.77±0.22 40.60±0.12 
105 60.63±0.18 61.1± 0.13 81.03±0.21 .41.1±0.12 
120 72.33±0.20 69.28±0.18 82.79±0.23 43.32±0.12 
 
Fig.16 :  In vitro dissolution profile of 5% alginate microspheres with 
different drug polymer ratio and % of cross linking agent 
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formulations FC1, FC2, FC3, FC4 
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Table 12 : Comparative In vitro dissolution profile of best 
formulations of 4%,5%,6% alginate microspheres 
FA2, FB2, FC2 
 
Fig. 17  Comparative In vitro dissolution profile of best formulations 
of 4%, 5%, 6% alginate microspheres FA2, FB2, FC2 
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Percentage of release  Time in 
minute FA2 FB2 FC2 
15 44.61±0.11 48.58±0.18 14.67±0.11 
30 50.13±0.19 66.98±0.19 23.48±0.12 
45 57.77±0.43 68.19±0.28 31.12±0.18 
60 58.50±0.29 69.93±0.13 41.10±0.19 
75 64.35±0.31 78.76±0.18 48.15±0.14 
90 67.77±0.52 80.97±0.17 59.30±0.14 
105 86.29±0.34 85.39±0.19 61.1± 0.13 
120 87.11±0.78 86.12±0.14 69.28±0.18 
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Invitro release studies from coated capsule 
 Microspheres equivalent to 50mg of  capecitabine were filled in a 
capsule (size No1) and sealed. Dissolution studies carried out in 900ml of 
pH progression medium at 370C and 60 rpm. The pH of the medium was 
gradually increased from pH 1.2 (0.1NHCl), pH 5.8, pH 6.8 phosphate 
buffer for 2 hours each respectively. Then transferred it to pH 7.6 
phosphate buffer until the end of the experiment. At specific time interval 
1,2,3,4 10hrs  dissolution sample is taken diluted to 1000ml using buffer 
solutions and quantified spectro photometrically at 239nm(Jain et al.,2005; 
Ziyaur et al.,2006) 
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Table 13 : In vitro dissolution study of formulation  (FA2) in Eudragit 
S-100 coated capsules 
Time in 
minutes 
Absorbance 
In nm 
Concentration
in mcg/ml 
Concentration 
in  mg/900ml 
Percentage 
release 
360 0 0 0 0 
420 0.016 0.4 0.4 0.39 
450 0.175 4.6 4.6 9.2 
465 0.296 7.8 7.8 13.44 
480 0.432 11.3 11.3 22.6 
495 0.511 13.4 13.4 26.8 
510 0.591 15.6 15.6 31.2 
525 0.662 17.3 17.3 34.6 
540 0.719 18.9 8.9 37.8 
555 0.771 20.2 20.2 40.4 
570 0.826 21.6 21.6 43.2 
585 0.85 23.2 23.3 46.4 
600 0.935 25.5 25.5 51 
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Fig.18: In vitro dissolution study of formulation   (FA2) in Eudragit  
S-100 coated capsules 
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RESULTS AND DISCUSSION 
COMPATIBILITY STUDIES 
 The compatibility between the drug Capecitabine and the selected 
polymer sodium alginate was evaluated using FT-IR peak matching method. The 
IR spectra of pure drug, polymer and physical mixture (1:1) were shown in 
spectra Fig: 3, 4, and 5 respectively. There was no appearance or disappearance 
of peaks in drug and polymer mixture which confirmed the absence of any 
chemical interaction between drug and polymer. 
PARTICLE SIZE AND SHAPE DETERMINATION USING MICROMETER AND 
SEM 
 Particle size determination studies were carried out on micrometric 
properties of the prepared microspheres which are shown in Table 5, 6 and 7. 
The arithmetic mean size of particles was about 14.86 to 25.4µm 
 Scanning electron microscopy reveals that the prepared microspheres 
had a homogeneous solid structure, with no evidences of crystals on the surface 
Fig. 9. The formulation  containing  capecitabine 4% sodium alginate 1:2 ratio 
with 2% calcium chloride (FA2) produced  by single emulsion technique enabled 
us to get spherical, discrete spheres with a size ranging from 10-30µm. 
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Entrapment efficiency  
 Entrapment efficiency of alginate microspheres was shown in Table 8. 
The entrapment efficiency of the microspheres is mainly altered by the drug 
polymer ratio, percentage of polymer and cross linking agent. The result indicate 
that the drug polymer 1:2 ratio with 4% polymer and 2% cross linking agent (FA2) 
shows a highest entrapment efficiency of 79.7%. Similarly 5% and 6% sodium 
alginate microspheres with the same drug polymer ratio1:2 and 2% percentage of 
cross linking agent (FB2 and FC2) had good entrapment efficiency 47.7%, 32.9% 
respectively. The above result clearly indicates higher drug entrapment efficiency 
at low concentration of polymer.  
IN VITRO RELEASE STUDIES. 
 The in vitro release profile of 4% sodium alginate with different drug 
polymer ratio and percentage of cross linking agent were carried out in 
phosphate buffer of pH 7.6 and the result is shown in Table 9, 10, 11 and 12 and 
Fig. 14, 15,16 and 17. In vitro release study reveals that drug polymer 1:2 ratio 
with 2% cross linking agent (FA2) showed a uniform release for 2 hrs than the 
other formulation containing 4% alginate. So, formulation FA2 was selected as 
better formulation. 
 Similar release pattern was observed in 5% and 6% alginate 
microspheres using 1:2 drug polymer ratio and 2% cross linking agent. 
 From the three selected formulation of (4% 5% 6% alginate microspheres) 
4% alginate microspheres had a good entrapment and release pattern than 
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the other two formulations. 
IN VITRO DRUG RELEASE STUDY OF FA4 CONTAINING EUDRAGIT  
S100 COATED CAPSULES 
        Dissolution study was carried out in simulated gastrointestinal tract 
conditions for Eudragit S100 coated capsule filled with (FA2) microspheres in  
pH1.2, pH 5.8.and pH 6.8 phosphate buffer revealed that there is no release of 
capecitabine from 10% Eudragit S100 coated 6 times by dipping method and it 
shows a good release pattern of capecitabine at pH 7.6 phosphate buffer shown 
in Table 13 and Fig. 18.  The study confirms that release rate of capecitabine 
from Eudragit S100 coated capsules was found to be pH dependent and is 
suitable for colon targeting. 
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SUMMARY AND CONCLUSION 
 Colorectal  carcinoma  is the second leading cancer  killer and third most  
common cancer throughout  the world. Capecitabine is a new drug for orally 
administered and widely used for the treatment of colorectal cancer. The first 
pass metabolism of capecitabine is a problem in achieving bioavailibility. 
Development of colon targeting microspheres will be the promising technique to 
avoid first pass metabolism and to achieve the desired bioavailibility profile.  
 The present investigation is focused on development of capecitabine 
loaded alginate microspheres and filled in capsules followed by Eudragit-S-100 
coating for targeting to colon region. The results suggested that drug,  4% sodium 
alginate  1:2 ratio with 2% cross linking agent (FA2) was found to be the best 
formulation and showed 87.1% release in 2hrs with 79.7% entrapment. So the 
formulation is selected for further coating with Eudragit-S-100 for targeting to 
colon region. The coated capsules release studies shows no evidence of drug 
release for up to 6hrs. It is evident that the GI emptying time can be bypassed by 
the coated capsules the drug release of 51% at the end of 10hrs from coated 
capsules. Suggests the Eudragit-S-100 coating only degrading in colon pH. The 
prepared formulation can be further evaluated in vivo for correlating in vitro study 
results. The prepared microspheres is a promising colon targeted delivery device 
for achieving better kinetic profile with improved  bioavailibility.            
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